Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on Gain Therapeutics, Inc. (NASDAQ:GANX) on July 01, 2026.
reiterateNASDAQ:GANX
HC Wainwright & Co. Reiterates Buy Rating on Gain Therapeutics, Inc. (GANX)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on Gain Therapeutics, Inc. (NASDAQ:GANX) on July 01, 2026.
Market Context
Gain Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $1.98 with a market capitalization of $148.5M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Gain Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Gain Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 30, 2026 | BTIG | Buy | N/A |
| Dec 19, 2025 | HC Wainwright & Co. | Buy | N/A |
| Oct 15, 2025 | BTIG | Buy | N/A |
| Oct 13, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View GANX Stock Page
Frequently Asked Questions
What does a Buy rating mean for GANX?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Gain Therapeutics, Inc. (NASDAQ:GANX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GANX forecast page.